Transdermal administration of tamsulosin
In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophobic synthetic rubber adhesive, (c) about 1-20 wt % of an aprotic solvent in which tamsulosin dissolves readily, (d) about 1-20 wt % of an unsaturated fatty acid or an alpha-hydroxy acid or a mixture of unsaturated fatty acids or alpha-hydroxy acids or of both unsaturated fatty acids and alpha-hydroxy acids, (e) a lipophilic permeation enhancer, and (f) a matrix modifier.
1. A method for treating a urological condition, comprising:
providing a transdermal patch comprising an adhesive matrix comprised of polyisobutylene, a solvent selected from dimethylacetamide, n-methylpyrrolidone and dimethylsulfoxide, a mixture of an unsaturated fatty acid and an alpha-hydroxy acid, a permeation enhancer of the formula CH 3 (CH 2 ) m OCOCHR1R2, where m is an integer in the range of 6 to 14, R1 and R2 are each independently selected from hydrogen, hydroxyl, and a C1-C2 lower alkyl group, wherein at least one of R1 and R2 is hydroxyl or both R1 and R2 are hydrogen, and tamsulosin; and
administering or instructing to administer the transdermal patch.
2. The method of claim 1 , wherein the solvent is dimethylsulfoxide.
3. The method of claim 2 , wherein the adhesive matrix comprises dimethylsulfoxide and tamsulosin in a weight ratio of at least 1.2.
4. The method of claim 1 , wherein the adhesive matrix comprises a molar ratio of alpha-hydroxy acid to tamsulosin of at least 0.1.
5. The method of claim 1 , wherein the unsaturated fatty acid is selected from the group consisting of oleic acid, linoleic acid, and linolenic acid.
6. The method of claim 1 , wherein the unsaturated fatty acid is a fatty acid with 11 to 21 carbon atoms.
7. The method of claim 1 , comprising at least about 40 wt % polyisobutylene.
8. The method of claim 1 , wherein the permeation enhancer is present at about 1-20 wt %.
9. The method of claim 1 , wherein the permeation enhancer is either methyl laurate or lauryl lactate.
10. The method of claim 1 , wherein tamsulosin is tamsulosin base.
11. The method of claim 1 , wherein the adhesive matrix further comprises colloidal silicone dioxide or fumed silica.
12. The method of claim 1 , wherein tamsulosin is a salt of tamsulosin and the matrix further comprises a neutralizing agent.
13. The method of claim 12 , wherein tamsulosin is tamsulosin hydrochloride.
14. The method of claim 1 , wherein the alpha-hydroxy acid is selected from the group consisting of lactic acid and glycolic acid.
15. A method for treating benign prostatic hyperplasia, comprising:
providing a transdermal patch comprising an adhesive matrix comprised of polyisobutylene, a solvent selected from dimethylacetamide, n-methylpyrrolidone and dimethylsulfoxide, a mixture of an unsaturated fatty acid and an alpha-hydroxy acid, a permeation enhancer of the formula CH 3 (CH 2 ) m OCOCHR1R2, where m is an integer in the range of 6 to 14, R1 and R2 are each independently selected from hydrogen, hydroxyl, and a C1-C2 lower alkyl group, wherein at least one of R1 and R2 is hydroxyl or both R1 and R2 are hydrogen, and tamsulosin; and
administering or instructing to administer the transdermal patch.
16. The method of claim 15 , wherein the solvent is dimethylsulfoxide.
17. The method of claim 15 , wherein tamsulosin is tamsulosin base.
18. The method of claim 15 , wherein the permeation enhancer is lauryl lactate.
19. The method of claim 15 , wherein the unsaturated fatty acid is oleic acid.